Syndax Pharmaceuticals' (NASDAQ:SNDX) Growing Losses Don't Faze Investors as the Stock Climbs 4.4% This Past Week
Syndax Pharmaceuticals' (NASDAQ:SNDX) Growing Losses Don't Faze Investors as the Stock Climbs 4.4% This Past Week
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) shareholders might be concerned after seeing the share price drop 11% in the last month. But that doesn't change the fact that the returns over the last five years have been very strong. In fact, the share price is 126% higher today. Generally speaking the long term returns will give you a better idea of business quality than short periods can. The more important question is whether the stock is too cheap or too expensive today.
近一个月来,Syndax Pharmaceuticals, Inc.(纳斯达克:SNDX)的股价下跌了11%,这可能会让股东们感到担忧。但是这并不改变过去五年的回报非常强劲的事实。实际上,股价今天比五年前高出126%。一般来说,长期回报可以更好地评估业务质量,短期回报则无法。更重要的问题是,该股票今天是否太便宜或太昂贵了。
The past week has proven to be lucrative for Syndax Pharmaceuticals investors, so let's see if fundamentals drove the company's five-year performance.
这一周对Syndax Pharmaceuticals的投资者来说非常有利,让我们看看基本面是否驱动了公司的五年表现。
Syndax Pharmaceuticals isn't currently profitable, so most analysts would look to revenue growth to get an idea of how fast the underlying business is growing. When a company doesn't make profits, we'd generally hope to see good revenue growth. As you can imagine, fast revenue growth, when maintained, often leads to fast profit growth.
Syndax Pharmaceuticals目前尚未盈利,因此大多数分析师会关注营收增长,以了解基本业务增长速度。当一家公司没有盈利时,我们通常希望看到良好的营收增长。正如你可以想象的,快速的营收增长,如果能够持续,就往往会导致快速的利润增长。
For the last half decade, Syndax Pharmaceuticals can boast revenue growth at a rate of 14% per year. That's a pretty good long term growth rate. We'd argue this growth has been reflected in the share price which has climbed at a rate of 18% per year over in that time. Given that the business has made good progress on the top line, it would be worth taking a look at the growth trend. When a growth trend accelerates, be it in revenue or earnings, it can indicate an inflection point for the business, which is can often be an opportunity for investors.
过去半个十年,Syndax Pharmaceuticals的营业收入每年以14%的速度增长,这是一个相当不错的长期增长率。我们认为这种增长已经反映在股价上,股价在那段时间内每年以18%的速度攀升。考虑到业务在销售额方面取得了良好的进展,值得注意的是增长趋势。当增长趋势加速时,无论是在营收还是在收益方面,都可能表明业务达到了拐点,这往往是投资者的机会。
The graphic below depicts how earnings and revenue have changed over time (unveil the exact values by clicking on the image).
下面的图表显示了收益和营收随时间的变化情况(通过单击图像揭示确切的值)。
![big](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240820/0-c801fed978c2cb3e51393bd8d9bd6a27-0-21330f4e69c448c9b4e3fabb147397c3.png/big)
Syndax Pharmaceuticals is a well known stock, with plenty of analyst coverage, suggesting some visibility into future growth. So we recommend checking out this free report showing consensus forecasts
Syndax Pharmaceuticals是一个知名的股票,有大量分析师关注,预示着未来增长的一些可见性。因此,我们建议查看这份免费报告,展示共识预测。
A Different Perspective
不同的观点
Syndax Pharmaceuticals shareholders are up 11% for the year. But that was short of the market average. If we look back over five years, the returns are even better, coming in at 18% per year for five years. It may well be that this is a business worth popping on the watching, given the continuing positive reception, over time, from the market. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. For instance, we've identified 3 warning signs for Syndax Pharmaceuticals that you should be aware of.
Syndax Pharmaceuticals的股东们今年已经获得了11%的回报,但是这还不及市场平均水平。如果我们回顾过去五年,回报甚至更好,五年的平均回报率为18%。考虑到市场对该公司的持续积极反应,这可能是一个值得关注的公司。虽然考虑到市场环境对股价可能造成的不同影响是很值得的,但还有其他更重要的因素。例如,我们已经确定了Syndax Pharmaceuticals的3个警示信号,你应该注意。
If you are like me, then you will not want to miss this free list of undervalued small caps that insiders are buying.
如果您像我一样,就不会希望错过这份免费的内部人士正在购买的低估小市值股票列表。
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges.
请注意,本文所引述的市场回报反映了目前在美国交易所上市的股票的市场加权平均回报。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对本文有任何反馈?对内容有任何疑虑?请直接与我们联系。或者,发送电子邮件至editorial-team@simplywallst.com。
这篇文章是Simply Wall St的一般性文章。我们根据历史数据和分析师预测提供评论,只使用公正的方法论,我们的文章并不意味着提供任何金融建议。文章不构成买卖任何股票的建议,也不考虑您的目标或您的财务状况。我们的目标是带给您基本数据驱动的长期关注分析。请注意,我们的分析可能不考虑最新的价格敏感公司公告或定性材料。Simply Wall St没有任何股票头寸。